TWO PART (DOUBLE-BLIND INCLISIRAN VERSUS PLACEBO [YEAR 1] FOLLOWED BY OPEN-LABEL INCLISIRAN YEAR 2]) RANDOMIZED MULTICENTER STUDY TO EVALUATE SAFETY, TOLERABILITY, AND EFFICACY OF INCLISIRAN IN ADOLESCENTS (12 TO LESS THAN 18 YEARS) WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA AND ELEVATED LDL-CHOLESTEROL (ORION-13)

Registry ID

CKJX839C12302

Source registry

HEALTH_CANADA

Status

Closed

Study type

INTERVENTIONAL

Sponsor

NOVARTIS PHARMACEUTICALS CANADA INC

Start date

2023-06-14

Completion date

2024-11-11

Last update

2020-12-21

Conditions

• HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA

Related clinical trials

• SAFETY AND EFFECTIVENESS OF EVINACUMAB FOR THE TREATMENT OF HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN A REAL LIFE SETTING IN CANADA
• PHASE 2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ARO-ANG3 IN SUBJECTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)
• A PHASE 2 OPEN-LABEL STUDY TO ASSESS THE PHARMACODYNAMICS, PHARMACOKINETICS, SAFETY AND TOLERABILITY OF ISIS 703802 (AKCEA-ANGPTL3LRX) ADMINISTERED SUBCUTANEOUSLY TO PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)
• AN OPEN-LABEL LONG-TERM EXTENSION TO THE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER, CROSS-OVER STUDY OF ROSUVASTATIN IN CHILDREN AND ADOLESCENTS (AGED 6 TO <18 YEARS) WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
• AN OPEN-LABEL, SINGLE-ARM, PROOF-OF-CONCEPT STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SINGLE AND MULTIPLE DOSES OF REGN1500 IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA

View on source registry